Impaired cytokines in diabetes and diabetic foot ulcers: mechanisms and prospects

Abstract

A pro-inflammatory state with elevated cytokines influenced by both environmental and genetic factors is a key characteristic of both type 1 diabetes (T1DM) and type 2 diabetes (T2DM). Cytokines promote immune cell infiltration and degradation of the pancreatic islets, which play a direct role in the development of insulin resistance in T1DM. Cytokines also interfere with insulin signaling pathways and lead to metabolic dysfunction, contributing to the development of insulin resistance in patients with T2DM. In this narrative review, we have discussed the mechanisms of action and specific effects on insulin resistance of different cytokines, the influence of single-nucleotide polymorphisms and genetic factors that alter cytokine levels, and the development of insulin resistance. Further, we have discussed the complication of diabetes with a focus on diabetic foot ulcers, wounds, impaired wound healing, and reduced angiogenesis in association with the role of cytokines. Finally, the discussion addresses interventions for managing cytokines, such as Treg-based therapies, along with the various challenges presented by therapies targeting cytokine dysregulation and their effects on insulin resistance.

Keywords

cytokines / type 1 diabetes / type 2 diabetes / diabetic foot ulcers / therapeutics

References

[1] de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008; 582: 97-105.

[2] Wondmkun YT. Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab Syndr Obes. 2020; 13: 3611-6.

[3] Venkatesan K, Paulsamy P, Alqahtani S, Asiri YI, Alqahtani T, Alqahtani A, et al. An update on the role of inflammation in insulin resistance and islet β cell failure-A crosstalk between immune cells, adipose tissue, cytokines, and oxidative stress. Lett Drug Des Discov. 2025; 22: 100023.

[4] Rai V, Moellmer R, Agrawal DK. The role of CXCL8 in chronic nonhealing diabetic foot ulcers and phenotypic changes in fibroblasts: a molecular perspective. Mol Biol Rep. 2022; 49: 1565-72.

[5] Shofler D, Rai V, Mansager S, Cramer K, Agrawal DK. Impact of resolvin mediators in the immunopathology of diabetes and wound healing. Expert Rev Clin Immunol. 2021; 17: 681-90.

[6] Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Clin Chim Acta. 2012; 413: 1163-70.

[7] Berbudi A, Khairani S, Tjahjadi AI. Interplay Between Insulin Resistance and Immune Dysregulation in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions. Immunotargets Ther. 2025; 14: 359-82.

[8] Berbudi A, Khairani S, Tjahjadi AI. Interplay Between Insulin Resistance and Immune Dysregulation in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions. Immunotargets Ther. 2025; 14: 359-82.

[9] Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF. Inflammatory cytokines in diabetic nephropathy. J Diabetes Res. 2015; 2015: 948417.

[10] Xiao J, Li J, Cai L, Chakrabarti S, Li X. Cytokines and diabetes research. J Diabetes Res. 2014; 2014: 920613.

[11] Hameed I, Masoodi SR, Mir SA, Nabi M, Ghazanfar K, Ganai BA. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World J Diabetes. 2015; 6: 598-612.

[12] Jin Z, Zhang Q, Liu K, Wang S, Yan Y, Zhang B, et al. The association between interleukin family and diabetes mellitus and its complications: An overview of systematic reviews and meta-analyses. Diabetes Res Clin Pract. 2024; 210: 111615.

[13] Johnson DR, O’Connor JC, Satpathy A, Freund GG. Cytokines in type 2 diabetes. Vitam Horm. 2006; 74: 405-41.

[14] Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005; 54 Suppl 2: S97-107.

[15] Rai U, Senapati D, Arora MK. Insights on the role of anti-inflammatory and immunosuppressive agents in the amelioration of diabetes. Diabetol Int. 2022; 14: 134-44.

[16] Grunnet LG, Aikin R, Tonnesen MF, Paraskevas S, Blaabjerg L, Størling J, et al. Proinflammatory cytokines activate the intrinsic apoptotic pathway in beta-cells. Diabetes. 2009; 58: 1807-15.

[17] Roy S, Pokharel P, Piganelli JD. Decoding the immune dance: Unraveling the interplay between beta cells and type 1 diabetes. Mol Metab. 2024; 88: 101998.

[18] Ge J, Yin X, Chen L. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations. Front Immunol. 2024; 15: 1457189.

[19] Zong Y, Deng K, Chong WP. Regulation of Treg cells by cytokine signaling and co-stimulatory molecules. Front Immunol. 2024; 15: 1387975.

[20] Komai T, Inoue M, Okamura T, Morita K, Iwasaki Y, Sumitomo S, et al. Transforming Growth Factor-β and Interleukin-10 Synergistically Regulate Humoral Immunity via Modulating Metabolic Signals. Front Immunol. 2018; 9: 1364.

[21] Arif S, Moore F, Marks K, Bouckenooghe T, Dayan CM, Planas R, et al. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death. Diabetes. 2011; 60: 2112-9.

[22] Asif R, Khalid A, Mercantepe T, Klisic A, Rafaqat S, Rafaqat S, et al. Role of Interleukins in Type 1 and Type 2 Diabetes. Diagnostics (Basel). 2025; 15: 1906.

[23] Wieser V, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp (Warsz). 2013; 61: 119-25.

[24] Roy PK, Rashid F, Bragg J, Ibdah JA. Role of the JNK signal transduction pathway in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 200-2.

[25] Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116: 1793-801.

[26] Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care. 2002; 5: 377-83.

[27] Shi J, Fan J, Su Q, Yang Z. Cytokines and Abnormal Glucose and Lipid Metabolism. Front Endocrinol (Lausanne). 2019; 10: 703.

[28] Zatterale F, Longo M, Naderi J, Raciti GA, Desiderio A, Miele C, et al. Chronic Adipose Tissue Inflammation Linking Obesity to Insulin Resistance and Type 2 Diabetes. Front Physiol. 2020; 10: 1607.

[29] Kim JJ, Sears DD. TLR4 and Insulin Resistance. Gastroenterol Res Pract. 2010; 2010: 212563.

[30] Yu W, Li C, Zhang D, Li Z, Xia P, Liu X, et al. Advances in T Cells Based on Inflammation in Metabolic Diseases. Cells. 2022; 11: 3554.

[31] Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022; 55: 31-55.

[32] Wei Q, Chen X, Chen H. Association of Single Nucleotide Polymorphisms of the IL-6, IL-10, and TNF-α Genes with Susceptibility to Gestational Diabetes Mellitus. Genet Test Mol Biomarkers. 2020; 24: 390-8.

[33] Ayelign B, Negash M, Andualem H, Wondemagegn T, Kassa E, Shibabaw T, et al. Association of IL-10 (-1082 A/G) and IL-6 (-174 G/C) gene polymorphism with type 2 diabetes mellitus in Ethiopia population. BMC Endocr Disord. 2021; 21: 70.

[34] Banerjee M, Saxena M. Genetic polymorphisms of cytokine genes in type 2 diabetes mellitus. World J Diabetes. 2014; 5: 493-504.

[35] Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005; 54: 2939-45.

[36] McArdle MA, Finucane OM, Connaughton RM, McMorrow AM, Roche HM. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol (Lausanne). 2013; 4: 52.

[37] Somm E, Jornayvaz FR. Interleukin-18 in metabolism: From mice physiology to human diseases. Front Endocrinol (Lausanne). 2022; 13: 971745.

[38] Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr. 2010; 91: 258S-61S.

[39] Benomar Y, Gertler A, De Lacy P, Crépin D, Ould Hamouda H, Riffault L, et al. Central resistin overexposure induces insulin resistance through toll-like receptor 4. Diabetes. 2013; 62: 102-14.

[40] Nashtahosseini Z, Eslami M, Paraandavaji E, Haraj A, Dowlat BF, Hosseinzadeh E, et al. Cytokine Signaling in Diabetic Neuropathy: A Key Player in Peripheral Nerve Damage. Biomedicines. 2025; 13: 589.

[41] Zheng H, Sun W, Zhang Q, Zhang Y, Ji L, Liu X, et al. Proinflammatory cytokines predict the incidence of diabetic peripheral neuropathy over 5 years in Chinese type 2 diabetes patients: A prospective cohort study. EClinicalMedicine. 2020; 31: 100649.

[42] Myers RR, Campana WM, Shubayev VI. The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov Today. 2006; 11: 8-20.

[43] Liu Y, Liu Y, Deng J, Li W, Nie X. Fibroblast Growth Factor in Diabetic Foot Ulcer: Progress and Therapeutic Prospects. Front Endocrinol (Lausanne). 2021; 12: 744868.

[44] Sawaya AP, Stone RC, Brooks SR, Pastar I, Jozic I, Hasneen K, et al. Deregulated immune cell recruitment orchestrated by FOXM1 impairs human diabetic wound healing. Nat Commun. 2020; 11: 4678.

[45] Lin CW, Hung CM, Chen WJ, Chen JC, Huang WY, Lu CS, et al. New Horizons of Macrophage Immunomodulation in the Healing of Diabetic Foot Ulcers. Pharmaceutics. 2022; 14: 2065.

[46] Blevins HM, Xu Y, Biby S, Zhang S. The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases. Front Aging Neurosci. 2022; 14: 879021.

[47] Cheng J, Qian W, Chen F, Liu X, Fu M, Cao W, et al. Function of epigenetic modifications in wound healing and potential therapies (Review). Int J Mol Med. 2025; 56: 190.

[48] Mahmoud NN, Hamad S, Shraim S. Inflammation-Modulating Biomedical Interventions for Diabetic Wound Healing: An Overview of Preclinical and Clinical Studies. ACS Omega. 2024; 9: 44860-75.

[49] Goswami AG, Basu S, Huda F, Pant J, Ghosh Kar A, Banerjee T, et al. An appraisal of vascular endothelial growth factor (VEGF): the dynamic molecule of wound healing and its current clinical applications. Growth Factors. 2022; 40: 73-88.

[50] Sun SY, Chen DW, Wu J, Li Y, Ran XW. Diabetic foot ulcer with overlap syndrome: A case report and review of literature. World J Diabetes. 2025; 16: 109597.

[51] Mohsin F, Javaid S, Tariq M, Mustafa M. Molecular immunological mechanisms of impaired wound healing in diabetic foot ulcers (DFU), current therapeutic strategies and future directions. Int Immunopharmacol. 2024; 139: 112713.

[52] Ghalami F, Binutha HR, Haghipanah M. Relationship between Pro-Inflammatory Cytokines and Growth Factors in Patients with Diabetic Foot Ulcers. GMJ Medicine. 2025; 4: 91-5.

[53] Smith J, Rai V. Novel Factors Regulating Proliferation, Migration, and Differentiation of Fibroblasts, Keratinocytes, and Vascular Smooth Muscle Cells during Wound Healing. Biomedicines. 2024; 12: 1939.

[54] Rai V, Moellmer R, Agrawal DK. Role of fibroblast plasticity and heterogeneity in modulating angiogenesis and healing in the diabetic foot ulcer. Mol Biol Rep. 2023; 50: 1913-29.

[55] Song J, Zhao T, Wang C, Sun X, Sun J, Zhang Z. Cell migration in diabetic wound healing: Molecular mechanisms and therapeutic strategies (Review). Int J Mol Med. 2025; 56: 126.

[56] Ding Y, Ding X, Zhang H, Li S, Yang P, Tan Q. Relevance of NLRP3 Inflammasome-Related Pathways in the Pathology of Diabetic Wound Healing and Possible Therapeutic Targets. Oxid Med Cell Longev. 2022; 2022: 9687925.

[57] Lee HS, Kim WJ. The Role of Matrix Metalloproteinase in Inflammation with a Focus on Infectious Diseases. Int J Mol Sci. 2022; 23: 10546.

[58] Dawi J, Tumanyan K, Tomas K, Misakyan Y, Gargaloyan A, Gonzalez E, et al. Diabetic Foot Ulcers: Pathophysiology, Immune Dysregulation, and Emerging Therapeutic Strategies. Biomedicines. 2025; 13: 1076.

[59] Huang K, Mi B, Xiong Y, Fu Z, Zhou W, Liu W, et al. Angiogenesis during diabetic wound repair: from mechanism to therapy opportunity. Burns Trauma. 2025; 13: tkae052.

[60] Rai V, Moellmer R, Agrawal DK. Stem Cells and Angiogenesis: Implications and Limitations in Enhancing Chronic Diabetic Foot Ulcer Healing. Cells. 2022; 11: 2287.

[61] Nirenjen S, Narayanan J, Tamilanban T, Subramaniyan V, Chitra V, Fuloria NK, et al. Exploring the contribution of pro-inflammatory cytokines to impaired wound healing in diabetes. Front Immunol. 2023; 14: 1216321.

[62] Kerstan A, Dieter K, Niebergall-Roth E, Klingele S, Jünger M, Hasslacher C, et al. Translational development of ABCB5⁺ dermal mesenchymal stem cells for therapeutic induction of angiogenesis in non-healing diabetic foot ulcers. Stem Cell Res Ther. 2022; 13: 455.

[63] Zhao Q, Xu J, Han X, Zhang Z, Qu J, Cheng Z. Growth differentiation factor 10 induces angiogenesis to promote wound healing in rats with diabetic foot ulcers by activating TGF-β1/Smad3 signaling pathway. Front Endocrinol (Lausanne). 2023; 13: 1013018.

[64] Maione AG, Smith A, Kashpur O, Yanez V, Knight E, Mooney DJ, et al. Altered ECM deposition by diabetic foot ulcer-derived fibroblasts implicates fibronectin in chronic wound repair. Wound Repair Regen. 2016; 24: 630-43.

[65] Acosta JB, del Barco DG, Vera DC, Savigne W, Lopez-Saura P, Guillen Nieto G, et al. The pro-inflammatory environment in recalcitrant diabetic foot wounds. Int Wound J. 2008; 5: 530-9.

[66] Chiu HS, Huang TS, Chen CT, Lin XY, Liao PC, Liou CC, et al. Temporal Regulation of Early-Stage Cytokine Expression in Diabetic Wound Healing Under Negative Pressure Wound Therapy. Int J Mol Sci. 2025; 26: 4634.

[67] Driver VR, Yao M, Kantarci A, Gu G, Park N, Hasturk H. A prospective, randomized clinical study evaluating the effect of transdermal continuous oxygen therapy on biological processes and foot ulcer healing in persons with diabetes mellitus. Ostomy Wound Manage. 2013; 59: 19-26.

[68] Yang Y, Zhang C, Jiang Y, He Y, Cai J, Liang L, et al. Harnessing cytokine-induced killer cells to accelerate diabetic wound healing: an approach to regulating post-traumatic inflammation. Regen Biomater. 2024; 11: rbad116.

[69] Qin Y, Deng S. Inflammation, diabetic foot and related treatments. Front Endocrinol (Lausanne). 2025; 16: 1676621.

[70] Miceli G, Basso MG, Pennacchio AR, Cocciola E, Pintus C, Cuffaro M, et al. The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives-A Narrative Review. Medicina (Kaunas). 2024; 60: 1796.

[71] Manzo Margiotta F, Michelucci A, Fidanzi C, Granieri G, Salvia G, Bevilacqua M, et al. Monoclonal Antibodies in the Management of Inflammation in Wound Healing: An Updated Literature Review. J Clin Med. 2024; 13: 4089.

[72] Cheng L, Rong X. Clinical application of biological agents in rheumatoid arthritis. Transpl Immunol. 2025; 89: 102187.

[73] Singh SK, Dwivedi SD, Yadav K, Shah K, Chauhan NS, Pradhan M, et al. Novel Biotherapeutics Targeting Biomolecular and Cellular Approaches in Diabetic Wound Healing. Biomedicines. 2023; 11: 613.

[74] Song J, Liu A, Liu B, Huang W, Jiang Z, Bai X, et al. Natural Biologics Accelerate Healing of Diabetic Foot Ulcers by Regulating Oxidative Stress. Front Biosci (Landmark Ed). 2022; 27: 285.

[75] Monaghan MG, Borah R, Thomsen C, Browne S. Thou shall not heal: Overcoming the non-healing behaviour of diabetic foot ulcers by engineering the inflammatory microenvironment. Adv Drug Deliv Rev. 2023; 203: 115120.

[76] Wabnitz GH, Balta E, Schindler S, Kirchgessner H, Jahraus B, Meuer S, et al. The pro-oxidative drug WF-10 inhibits serial killing by primary human cytotoxic T-cells. Cell Death Discov. 2016; 2: 16057.

[77] Li P, Zheng Y, Chen X. Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Front Pharmacol. 2017; 8: 460.

[78] Mickael ME, Kubick N, Miftari K, Horbańczuk JO, Atanasov AG, Binçe K, et al. The Role of Th17/Treg Axis in Retinal Pathology Associated with Diabetes and Treatment Options. Biology (Basel). 2025; 14: 275.

[79] Xiong G, Chen Q, Wang Q, Wang X, Xiao Y, Jin L, et al. Multifaceted role of nanocomposite hydrogels in diabetic wound healing: enhanced biomedical applications and detailed molecular mechanisms. Biomater Sci. 2024; 12: 6196-223.

[80] Yadav PS, Singh M, Vinayagam R, Shukla P. Therapies and delivery systems for diabetic wound care: current insights and future directions. Front Pharmacol. 2025; 16: 1628252.

[81] Umekar M, Chaudhary AA, Manghani M, Shidhaye S, Khajone P, Mahore J, et al. Probiotics in Nanotechnology-Driven Wound Healing: From Mechanistic Insight to Clinical Promise. Pharmaceutics. 2025; 17: 805.

[82] Piemonti L, Keymeulen B, Gillard P, Linn T, Bosi E, Rose L, et al. Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2022; 24: 1840-9.

[83] He J, Dai P, Liu L, Yang Y, Liu X, Li Y, et al. The effect of short-term intensive insulin therapy on inflammatory cytokines in patients with newly diagnosed type 2 diabetes. J Diabetes. 2022; 14: 192-204.

[84] Genovese MC, Burmester GR, Hagino O, Thangavelu K, Iglesias-Rodriguez M, John GS, et al. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Res Ther. 2020; 22: 206.

[85] Luo J, Ning T, Li X, Jiang T, Tan S, Ma D. Targeting IL-12 family cytokines: A potential strategy for type 1 and type 2 diabetes mellitus. Biomed Pharmacother. 2024; 170: 115958.

[86] Zhou JY, Chan L, Zhou SW. Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol. 2014; 12: 136-43.

[87] Sena CM. Omentin: A Key Player in Glucose Homeostasis, Atheroprotection, and Anti-Inflammatory Potential for Cardiovascular Health in Obesity and Diabetes. Biomedicines. 2024; 12: 284.

[88] de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007; 56: 1655-61.

[89] Eimal Latif AH, Anwar S, Gautham KS, Kadurei F, Ojo RO, Hafizyar F, et al. Association of Plasma Omentin-1 Levels With Diabetes and Its Complications. Cureus. 2021; 13: e18203.

[90] Dan X, Li K, Xu J, Yan P. The Potential of Neuregulin 4 as a Novel Biomarker and Therapeutic Agent for Vascular Complications in Type 2 Diabetes Mellitus. J Inflamm Res. 2024; 17: 8543-54.

[91] Wang H, Wang L, Hu F, Wang P, Xie Y, Li F, et al. Neuregulin-4 attenuates diabetic cardiomyopathy by regulating autophagy via the AMPK/mTOR signalling pathway. Cardiovasc Diabetol. 2022; 21: 205.

[92] Kocak MZ, Aktas G, Erkus E, Yis OM, Duman TT, Atak BM, et al. Neuregulin-4 is associated with plasma glucose and increased risk of type 2 diabetes mellitus. Swiss Med Wkly. 2019; 149: w20139.

[93] Akshay D, Chauhan A, Goyal P, Pranesh V. Study of neuregulin-4 levels in newly diagnosed type 2 diabetes mellitus. J Family Med Prim Care. 2023; 12: 2888-93.

[94] S AK, Patel SS. Possible Drug Repurposing and Accelerated Wound Healing. Regen Eng Transl Med. 2025; 11: 76-87.

[95] Tappen RM, Wolf DG, Rahemi Z, Engstrom G, Rojido C, Shutes JM, et al. Barriers and Facilitators to Implementing a Change Initiative in Long-Term Care Using the INTERACT® Quality Improvement Program. Health Care Manag (Frederick). 2017; 36: 219-30.

[96] Owusu LB, Scheepers N, Tenza IS. Barriers and facilitators influencing research utilization in clinical nursing and midwifery: an exploratory qualitative study. Int J Nurs Stud Adv. 2025; 8: 100354.

[97] Langmack EL, Ravyn D, Lowney R, Goodwin B, Lumry WR. Barriers and promoters to adapting research findings to clinical care in hereditary angioedema in the United States: A qualitative study. PLoS One. 2025; 20:e0329585.

[98] Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Standards for Developing Trustworthy Clinical Practice Guidelines. In: Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, editors. Clinical Practice Guidelines We Can Trust. Washington (DC): National Academies Press (US); 2011.

[99] Wang T, Tan JB, Liu XL, Zhao I. Barriers and enablers to implementing clinical practice guidelines in primary care: an overview of systematic reviews. BMJ Open. 2023; 13:e062158.